Cefepime Dosing for CKD Stage 3
For adults with CKD stage 3 (eGFR 30-59 mL/min), adjust cefepime to 1-2 g every 24 hours depending on infection severity, or 2 g every 12 hours for severe infections requiring higher doses.
Dosing Algorithm by Creatinine Clearance
The FDA-approved dosing adjustments for cefepime in renal impairment are based on creatinine clearance (CrCl), which corresponds to CKD stage 3 1:
For CrCl 30-60 mL/min (CKD 3):
- Mild-moderate UTI: 500 mg every 24 hours
- Standard infections (pneumonia, skin/soft tissue): 1 g every 24 hours
- Severe infections (complicated UTI, severe pneumonia): 2 g every 24 hours
- Febrile neutropenia or Pseudomonas coverage: 2 g every 12 hours
The initial loading dose should match the normal renal function dose before transitioning to the adjusted maintenance schedule 1.
Key Clinical Considerations
Renal function estimation matters: Use the Cockcroft-Gault equation to calculate CrCl for dosing decisions, as this is what the FDA label and clinical trials used 1. The newer CKD-EPI equations may overestimate GFR by 4-5 mL/min/1.73m² compared to older equations, potentially leading to overdosing 2.
Neurotoxicity risk increases significantly in CKD: Cefepime accumulation causes encephalopathy, confusion, myoclonus, and seizures, particularly when trough concentrations exceed 20-35 mg/L 3, 4, 5. This occurs in approximately 10% of patients with renal impairment despite dose adjustment 4. The risk is highest with:
- CrCl <30 mL/min
- Pre-existing neurological conditions
- Failure to adjust doses appropriately
Monitor for hidden neurotoxicity: Non-convulsive symptoms (confusion, muscle jerks) may not be immediately attributed to cefepime 4. If unexplained neurological changes occur, consider therapeutic drug monitoring (TDM) and temporarily discontinue cefepime 3, 5.
Pharmacokinetic Rationale
Cefepime elimination half-life increases from 2 hours in normal renal function to 13.5 hours in patients requiring hemodialysis 6. Total body clearance decreases proportionally with creatinine clearance 6. In CKD stage 3, the clearance reduction necessitates either dose reduction or interval extension to prevent accumulation 7, 6.
Recent population PK studies in critically ill patients suggest that for CKD 3 with severe infections, extended infusion strategies (e.g., 2 g over 4 hours every 12 hours) may optimize the pharmacodynamic target (time above MIC) while minimizing neurotoxicity risk 7, 5. However, standard 30-minute infusions remain the FDA-approved method 1.
Practical Pitfalls to Avoid
Don't use normal dosing in CKD 3: Even mild renal impairment (CrCl 50 mL/min) requires adjustment to prevent accumulation 1, 6
Don't rely solely on serum creatinine: Calculate actual CrCl using Cockcroft-Gault with current weight and age 1
Don't ignore dynamic renal function: Renal function can fluctuate in acute illness; reassess CrCl if clinical status changes 7, 5
Don't overlook the lower threshold: If CrCl drops below 30 mL/min (CKD 4), further dose reduction to 500 mg-1 g every 24 hours is required 1